<h4>Background</h4>Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are widely used in the treatment of estrogen receptor-positive (ER<sup>+</sup>) breast cancer; however, the metabolic adaptations induced by CDK4/6 inhibition remain incompletely defined. This evidence concerns the gene ESR1 and breast cancer.